Clinical and experimental studies on lymph node metastasis in lung cancer

1.Cox多因素分析表明，DNA倍体和肿瘤大小是1期肺癌的重要预后因素。DNA非整倍体肿瘤可能有淋巴结微转移和亚临床远处转移。转移性淋巴结窦组织细胞增生（SH）和滤泡增生（FH）程度与组织学类型无关。高SH腺癌和高FH鳞状细胞癌预后良好。活化的基质金属蛋白酶（MMP-2）在癌组织中特异性发现。其在淋巴结累及肿瘤中的活性明显高于淋巴结阴性肿瘤。膜型MMP在肿瘤组织中过表达，MMP2的活性与mt -MMP的表达有一定关系。淋巴结转移频率与肿瘤大小呈正相关，而与PCNA标记指数（LI） %无关。当肿瘤直径小于30mm且PCNA LI%高时，无淋巴结转移。即使在相同的DNA倍性模式下，也检测到PCNA LI%的差异。流式细胞仪检测PCNA和DNA含量的双染色技术为评价肺癌的恶性潜能提供了有用的生物学参数。M109小鼠模型治疗晚期肺癌的实验研究表明，术前全身化疗和放疗可有效减少淋巴结和肺部转移灶的数量。

1.Cox's multivariate analysis clarified that DNA ploidy and tumor size were significant prognostic factors of stage-1 lung cancer. DNA aneuploid tumors might have lymphnode micrometastasis and subclinical distant metastasis.2.There was no relationship between the degree of sinus histiocytosis (SH) and follicular hyperplasia (FH) of metastatic lymph nodes, and histological types. But the high SH adenocarcinomas and the high FH squamous cell carcinomas showed favorable prognosis.3.The activated matrix-metalloproteinase (MMP-2) was found specifically in cancer tissue. And its activity in the tumors with lymph node involvement was significantly higher than nodenegative ones. Membranous-type MMP was over-expressed in the tumor tissue, and there was relationship between the activity of MMP2 and the expression of MT-MMP.4.The frequency of lymphnode metastasis correlated positively with tumor size but not with PCNA labeling index (LI) %. There was no lymphnode metastasis when the tumor was less than 30mm in diameter and the PCNA LI% was high. Difference of PCNA LI% were detected even in the same DNA ploidy pattern. The double staining technique of PCNA and DNA contents with FCM provided useful biological parameters in evaluating the malignant potential of lung cancer.5.Experimental study of therapy of advanced lung cancer by M109 mouse model showed that preoperative systemic chemo-and radiation therapy was effective to reduce the number of metastatic lesions to lymphnodes and lungs.